Mucosal vaccines, sterilizing immunity, and the future of SARS-CoV-2 virulence

D Focosi, F Maggi, A Casadevall - Viruses, 2022 - mdpi.com
Sterilizing immunity after vaccination is desirable to prevent the spread of infection from
vaccinees, which can be especially dangerous in hospital settings while managing frail …

Approaches and challenges in SARS-CoV-2 vaccine development

G Dagotto, J Yu, DH Barouch - Cell host & microbe, 2020 - cell.com
The explosive spread of SARS-CoV-2 suggests that a vaccine will be required to end this
global pandemic. Progress in SARS-CoV-2 vaccine development to date has been faster …

[HTML][HTML] COVID‐19: Current knowledge in clinical features, immunological responses, and vaccine development

R Singh, A Kang, X Luo, M Jeyanathan… - The FASEB …, 2021 - ncbi.nlm.nih.gov
The COVID‐19 pandemic has unfolded to be the most challenging global health crisis in a
century. In 11 months since its first emergence, according to WHO, the causative infectious …

The evolution of poxvirus vaccines

L Sánchez-Sampedro, B Perdiguero, E Mejías-Pérez… - Viruses, 2015 - mdpi.com
After Edward Jenner established human vaccination over 200 years ago, attenuated
poxviruses became key players to contain the deadliest virus of its own family: Variola virus …

Intranasal and oral vaccination with protein-based antigens: advantages, challenges and formulation strategies

S Wang, H Liu, X Zhang, F Qian - Protein & cell, 2015 - academic.oup.com
Most pathogens initiate their infections at the human mucosal surface. Therefore, mucosal
vaccination, especially through oral or intranasal administration routes, is highly desired for …

Development of SARS-CoV-2 vaccines: should we focus on mucosal immunity?

L Moreno-Fierros, I García-Silva… - Expert Opinion on …, 2020 - Taylor & Francis
The COVID-19 pandemic caused by the SARS-CoV-2 virus is having an unprecedented
impact on global health derived from its quick spread, which is attributed to its high stability …

Enhancing poxvirus vectors vaccine immunogenicity

J García-Arriaza, M Esteban - Human vaccines & …, 2014 - Taylor & Francis
Attenuated recombinant poxvirus vectors expressing heterologous antigens from pathogens
are currently at various stages in clinical trials with the aim to establish their efficacy. This is …

Single-dose replicating poxvirus vector-based RBD vaccine drives robust humoral and T cell immune response against SARS-CoV-2 infection

S Boulton, J Poutou, NT Martin, T Azad, R Singaravelu… - Molecular Therapy, 2022 - cell.com
The coronavirus disease 2019 (COVID-19) pandemic requires the continued development
of safe, long-lasting, and efficacious vaccines for preventive responses to major outbreaks …

An insight into current treatment strategies, their limitations, and ongoing developments in vaccine technologies against herpes simplex infections

D Sharma, S Sharma, N Akojwar, A Dondulkar… - Vaccines, 2023 - mdpi.com
Herpes simplex virus (HSV) infection, the most prevalent viral infection that typically lasts for
a lifetime, is associated with frequent outbreaks of oral and genital lesions. Oral herpes …

AT cell-targeted multi-antigen vaccine generates robust cellular and humoral immunity against SARS-CoV-2 infection

S Boulton, J Poutou, R Gill, N Alluqmani, X He… - … Therapy-Methods & …, 2023 - cell.com
SARS-CoV-2, the etiological agent behind the coronavirus disease 2019 (COVID-19)
pandemic, has continued to mutate and create new variants with increased resistance …